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Abstract 
 
Background: Re-experiencing is a core symptom in the diagnosis of Posttraumatic Stress 
Disorder (PTSD). Patients regard re-experiencing as the most distressing symptom and it 
greatly impairs the functionality. Narrative Exposure Therapy (NET) is a relatively new 
evidence based treatment for PTSD. In this study, we investigated the effectiveness of NET 
on re-experiencing symptoms in early childhood trauma-related PTSD. Method: Four 
patients of the department of Psychotrauma at PsyQ Den Haag who were at the waiting list 
were included. They all suffered from PTSD related to early childhood trauma (< 16 years 
old). All participants received a maximum of 20 NET sessions of approximately 90 minutes 
each. Data was collected with the Posttraumatic Diagnostic Scale and the Manchester short 
assessment of quality of life VN-12. A visual inspection, a time series analysis and a mixed 
models analysis were performed. The clinical significance was tested with the Reliable 
Change Index. Results: There was no clinically significant decrease in re-experiencing 
symptoms. Visual inspection did not show a positive correlation between the number of 
completed NET sessions and the reduction in re-experiencing symptoms. There was no 
clinically significant increase in the quality of life. Conclusion: NET does not have a 
clinically significant effect on the frequency of re-experiencing symptoms and the quality of 
life in patients with PTSD due to early childhood trauma in this study. Further research is 
required to determine the effectiveness of NET on patients with early childhood trauma-
related PTSD. 
 
Keywords: early childhood trauma, posttraumatic stress disorder, narrative exposure therapy, 
re-experiencing symptoms, single-case experimental design 
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1. Introduction 
1.1 Posttraumatic stress disorder 
Experiencing a traumatic event which involved actual or threatened death, serious injury or 
sexual violence can result in posttraumatic stress disorder (PTSD) (Ehlers & Clark, 2000; 
Rachman, 2013; American Psychiatric Association [APA], 2013). Other ways to develop 
PTSD, instead of experiencing a traumatic event yourself, are witnessing the traumatic event 
occur to someone else, learning about the traumatic event which occurred to a family member 
or close friend, or indirect exposure to aversive details of the traumatic event (APA, 2013). 
Examples of traumatic events which qualify to develop PTSD are: directly experiencing 
physical abuse, witnessing a severe accident, learning about sexual violence related to a loved 
one, or being a police officer in a child abuse case. 
According to recent research in The Netherlands, the lifetime prevalence to experience 
a traumatic event is 80.7% and to develop PTSD is 7.4% (De Vries & Olff, 2009). Research 
found that the prevalence of PTSD is higher among women and people who have been 
married before (Kessler, Sonnega, Bromet, Hughes, & Nelson, 1995). Another finding is that 
for both men and women the traumatic event associated with the highest probability of 
developing PTSD is rape. Other traumatic events associated with a high probability of 
developing PTSD are exposure to combat for men and childhood physical abuse for women 
(Kessler et al., 1995). There’s a high comorbidity with other disorders: research showed that 
59% of men and 43.6% of women with PTSD have more than 3 psychiatric diagnoses 
(Kessler et al., 1995).  
 
PTSD was first described in the DSM-III and was characterized by re-experiencing the 
traumatic event, withdrawal from the external world, and other cognitive, autonomic and 
dysphoric symptoms (APA, 1980). In accordance with the DSM-III, the DSM-IV and the 
DSM-IV-TR classified PTSD as an anxiety disorder (APA, 1994; APA, 2000). From 2017 
onwards the DSM-5 will be used in The Netherlands. Herein PTSD is placed in the category 
‘Trauma- and Stressor-Related Disorders’ (APA, 2013). The differences between the DSM-
IV-TR and DSM-5 for the diagnosis PTSD are shown in Table 1. 
The main symptoms of PTSD in the DSM-5 include re-experiencing the traumatic 
event, avoidance of trauma related stimuli, negative alterations in mood and/or cognition and 
hyperarousal (APA, 2013). Over the years, re-experiencing remained one of the stable main 
symptoms of the diagnosis PTSD (Brewin, 2015). This category includes intrusions, 
nightmares, flashbacks, emotional and physical reactivity. Characteristic for re-experiencing 
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is an involuntary, obtrusive memory of the traumatic event which calls on sensory 
impressions instead of thoughts, and the feeling that the traumatic event occurs again (Ehlers, 
Hackmann & Michael, 2004; Brewin, 2014). These involuntary re-experiencing symptoms 
can be triggered by internal and external stimuli, which are cues that were present before or 
during the traumatic event and hereby became associated (Ehlers & Clark, 2000). Examples 
of external cues are: seeing someone who looks like the perpetrator, a certain smell, or being 
touched at specific parts of your body, while an emotional state is an example of an internal 
cue. Patients report re-experiencing as most distressing symptom that impairs their 
functionality (Brewin & Holmes, 2003; Brewin, 2015). 
 
Table 1. PTSD diagnosis in the DSM-IV-TR and the DSM-5 
DSM-IV-TR items  DSM-5 items  
A. Traumatic event 
(A1 and A2 must be 
present) 
A1: Experienced, witnessed, or 
confronted with event(s) that 
involved actual or threatened 
death, serious injury, or a threat 
to physical integrity of 
self/others 
A2: The person’s response 
involved intense fear, 
helplessness or horror 
A. Traumatic event 
(one or more must 
be present) 
Exposure to actual or threatened 
death, serious injury or sexual 
violence  
A1: Directly experiencing 
A2: Witnessing  
A3: Learning about occurrence to 
a family member or a friend 
A4: Repeated or extreme 
exposure to aversive details 
B. Re-experiencing 
(one or more must 
be present)  
 
B1: Intrusions 
B2: Nightmares 
B3: Flashbacks 
B4: Emotional reactivity 
B5: Physical reactivity 
B. Re-experiencing 
(one or more must 
be present) 
B1: Intrusions 
B2: Nightmares 
B3: Flashbacks 
B4: Emotional reactivity 
B5: Physical reactivity 
C. Avoidance 
(three or more must 
be present) 
C1: Avoid thoughts/feelings 
C2: Avoid places/activities 
C3: Amnesia 
C4: Loss of interest 
C5: Social detachment 
C6: Psychological numbing 
C7: Foreshortened future 
C. Avoidance 
(one or more must 
be present) 
 
D. Negative 
alterations in 
cognitions/mood 
(two or more must 
be present) 
C1: Avoid thoughts/feelings 
C2: Avoid external reminders† 
 
D1: Amnesia 
D2: Negative beliefs† 
D3: Distorted blame† 
D4: Negative emotional state† 
D5: Loss of interest 
D6: Social detachment 
D7: Low positive emotions† 
D. Hyperarousal 
(two or more must 
be present) 
D1: Sleep disturbance 
D2: Irritability/anger outbursts 
D3: Difficulty concentrating 
D4: Hypervigilance 
D5: Exaggerated startle 
response 
E. Hyperarousal 
(two or more must 
be present) 
E1: Aggression/irritability/anger† 
E2: Reckless/self-destructive† 
E3: Hypervigilance 
E4: Exaggerated startle response 
E5: Difficulty concentrating 
E6: Sleep disturbance 
E. Duration  B, C and D must be present for 
at least 1 month 
F. Duration B, C, D and E must be present 
for at least 1 month 
F. Disturbance Causes significant distress or 
functional impairment 
G. Disturbance Causes significant distress or 
functional impairment 
  H. Attributable Symptoms are not attributable to 
substances or to a medical 
condition†  
† Not included in the DSM-IV-TR 
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1.2 Early childhood trauma 
Among adults who survived early childhood trauma the prevalence to develop PTSD ranges 
from 34% to 42% (Astin et al., 1995; Kessler et al., 1995). Early childhood trauma can be 
defined as any form of threatening or violent interaction of physical, psychological or sexual 
nature to an under-aged minor, causing serious or threatening harm in the form of physical or 
psychological injury (Jongedijk, 2014). These traumatic events may qualify to develop PTSD 
as described in the DSM-5 (APA, 2013). The age limits to define early childhood trauma 
differ between studies, for this research an age limit of 16 years old for the first traumatic 
event to happen is maintained. 
Since the traumatic event took place in the formative years of the child, it can cause 
multiple adverse effects (Stovall-McClough & Cloitre, 2006). Adults with PTSD due to early 
childhood trauma often also experience anxiety, depression, suicidality, dissociation, or suffer 
from personality disorders or substance abuse. Sexual abuse during childhood can specifically 
cause impaired sexual functioning, interpersonal problems and physical illness in adults 
(Yehuda, Halligan & Grossman, 2001; Cloitre et al., 2010). 
 
Evidence based treatments are available for adults with early childhood trauma-related PTSD. 
A meta-analysis of 16 randomized controlled trials compared the effectiveness of 
psychological treatments for PTSD in adult survivors of childhood abuse (Ehring et al., 2014). 
These psychological treatments were: trauma-focused cognitive-behavioural therapy (TF-
CBT), non-trauma-focused cognitive behavioural therapy, eye movement desensitization and 
reprocessing (EMDR), interpersonal therapy and emotion-focused therapy. The meta-analysis 
showed that exposure-based treatments are more effective than non-exposure-based 
treatments, and individual trauma-focused treatments are most effective (Ehring et al., 2014).  
Trauma-focused treatments directly address thoughts, feelings and/or memories of the 
traumatic event to reduce PTSD symptoms, examples are EMDR and TF-CBT (Cusack et al., 
2016). EMDR lets the patient focus on a traumatic mental image, connected emotions and/or 
cognitions. Meanwhile, the therapist offers eye-movements, or auditory or tactile stimuli. 
Examples of TF-CBT are cognitive restructuring or stimulus confrontation, such as imaginal 
or in vivo exposure (Richards, Lovell & Marks, 1994). Both EMDR and TF-CBT reduce 
PTSD symptoms and help restoring the traumatic memory in a more neutral way (Tarrier et 
al., 1999; Seidler & Wagner, 2006).   
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1.3 Narrative exposure therapy 
In the field of psychological treatments, narrative exposure therapy (NET) is a relatively new 
evidence based treatment for PTSD. NET is a form of short-term exposure-based individual 
TF-CBT (Jongedijk, 2014). During the sessions the patient and therapist will make a 
chronological reconstruction of the patient’s personal narrative, in which all lifetime traumatic 
and positive events will get a place (Jongedijk, 2014). This lifeline is visualized with a rope, 
where negative or traumatic events are symbolized using stones and positive events are 
symbolized with (artificial) flowers. The working mechanism of NET consists of the 
activation of anxiety-evoking memories by exposure and encoding these explicit trauma-
related memories, so they can be stored again in a more neutral way (Robjant & Fazel, 2010).  
NET was initially designed to treat PTSD in refugees and is well-accepted because of 
its culturally sensitive character. In both high and low-income countries results showed that 
NET is an effective treatment for PTSD (Robjant & Fazel, 2010). A randomized controlled 
trial among Sudanese refugees who suffered from PTSD and were living in a refugee 
settlement in Uganda compared the effect of three forms of treatments: 4 sessions of NET, 4 
sessions of supportive counselling or 1 session of psycho-education (Neuner et al., 2004). At 
the post-treatment, both NET and supportive counselling contributed to a decrease of PTSD 
symptoms. Four months after treatment, all groups showed an increase of PTSD symptoms. 
This could possibly be attributed to external circumstances, such as shortage of food and the 
threat of being forced to move to locations where the traumatic events took place. However, 
one year after treatment only 29% of the NET group still fulfilled the PTSD-criteria in 
comparison to 79% of the supportive counselling group and 80% of the psychoeducation 
group (Neuner et al., 2004). The preliminary randomized clinical trial of Hijazi et al. (2014) 
showed that 3 sessions of NET reduced PTSD symptoms in traumatized Iraqi refugees in the 
United States (d = -.48). Two months after completion of NET the decrease in PTSD 
symptoms differed from the control group, after four months the control group also showed a 
decrease in PTSD symptoms (Hijazi et al., 2014). A review of 9 studies evaluated the 
effectiveness of NET in refugees, orphans and asylum seekers (Robjant & Fazel, 2010). The 
review compared NET to control treatments such as psychoeducation, supportive counselling, 
meditation-relaxation, trauma counselling (stabilisation), interpersonal group therapy, a 
waiting list control group, treatment as usual and two studies who did not use a control 
treatment. The review showed the effectiveness of NET in reducing PTSD symptoms and 
superiority over the other treatments (Robjant & Fazel, 2010).  
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Preliminary research shows positive outcomes for other populations as well, such as 
patients with comorbid psychiatric disorders and survivors of early childhood abuse. In a pilot 
study of Steuwe et al. (2016) NET was evaluated as an add-on in patients with PTSD and 
comorbid borderline personality disorder. The study followed 11 patients for 10 weekly NET-
sessions: a remission rate of 37.5% and a large effect size (d = 1.7) was reported (Steuwe et 
al., 2016). An open study conducted in Japan with NET on 5 patients with early childhood 
trauma-related PTSD showed a significant reduction in PTSD symptoms (Dõmen et al., 2012, 
as cited in Jongedijk, 2014). However, the study was published in Japanese, which makes it 
hard to evaluate the quality. Therefore, further research is recommended to determine the 
effectiveness of NET on early childhood trauma-related PTSD. For future research, a 
randomized controlled trial does not seem suitable because of the insufficient amount of 
evidence for NET in early childhood trauma-related PTSD, a single case study seems more 
appropriate to explore the effectiveness. Thereby, a single case study permits the study of 
individual differences which are not likely to be studied in between-group research.  
 
1.4 Research question and hypotheses 
The aim of this study is to investigate the effectiveness of narrative exposure therapy (NET) 
on re-experiencing symptoms in early childhood trauma-related posttraumatic stress disorder 
(PTSD). Patients regard re-experiencing as the most distressing symptom of PTSD and it 
greatly impairs their functionality (Brewin & Holmes, 2003; Brewin, 2015). Re-experiencing 
the traumatic event is a core symptom in the diagnosis of PTSD, which would make the 
results well generalizable (APA, 2013). Re-experiencing symptoms have not been studied 
apart from other PTSD-symptoms in therapy effect studies before.  
In the case of early childhood trauma-related PTSD, NET-studies are under-
represented. The study of Dõmen et al. (2012, as cited in Jongedijk, 2014) showed promising, 
but preliminary, results on the effectiveness of NET in early childhood trauma-related PTSD. 
Therefore, further research on the effectiveness of NET in early childhood trauma-related 
PTSD is recommended.  
 
In order to answer the research question, the following hypotheses are formulated: 
1. The frequency of re-experiencing symptoms decreases more during the treatment 
phase than during the baseline phase (hypothesis 1a). Re-experiencing symptoms are 
clinically significantly decreased in frequency at the end of the treatment phase in 
comparison to the baseline phase (hypothesis 1b). 
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2. There is a positive correlation between the number of completed NET sessions and the 
reduction in re-experiencing symptoms. 
3. The quality of life increases more during the treatment phase than during the baseline 
phase (hypothesis 3a). The quality of life is clinically significantly increased at the end 
of the treatment phase in comparison to the baseline phase (hypothesis 3b).  
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2. Methods 
This study is part of a larger research on the effectiveness of Narrative Exposure Therapy 
(NET) on early childhood trauma-related PTSD. The entire study on the effectiveness of NET 
on PTSD involves eight individual participants as single-cases, while this study will focus on 
four of those participants. 
This study will be written as a master thesis for the master Clinical Psychology at the 
Universiteit Leiden. 
 
2.1 Single-case experimental design 
The study will use a single-case experimental AB-design to explore whether NET provides a 
decrease in re-experiencing symptoms and an increase in quality of life ratings in patients 
with early childhood trauma-related PTSD (Barlow, Hersen & Jackson, 1973). 
The single-case experimental design will use multiple baseline assessments of the four 
participants, these assessments will be used to compare to later treatment measurements and 
draw final conclusions. A noncurrent multiple baseline will be used, since not all participants 
will start at the same time with treatment (Kazdin, 2017). 
 
2.2 Participants 
The participants are patients of the department of Psychotrauma at PsyQ Den Haag. All 
participants suffer from PTSD related to childhood trauma and are placed on the waiting list 
for treatment.  
The inclusion and exclusion criteria will be assessed with the Mini-International 
Neuropsychiatric Interview Plus 5.0 (MINI; Sheehan et al., 2006) and the Clinician 
Administered PTSD Scale (CAPS; Blake et al., 1990). This study is part of a larger research 
which started before the introduction of the Dutch DSM-5 in 2017 and thereby will use the 
DSM-IV-TR PTSD-diagnosis. Inclusion criteria are PTSD related to childhood trauma (< 16 
years old), indication for ‘Verwerking’ (trauma-focused treatment) and speaking the Dutch 
language. Exclusion criteria are psychosis, severe depression with suicidal intentions, abuse 
or dependence of alcohol or drugs, medication which is not stable for over one month or non-
suicidal self-injury less than two months ago with medical consequences.  
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2.3 Measures 
The MINI (Sheehan et al., 2006) and the CAPS (Blake et al., 1990) will be used to diagnose 
PTSD. The Posttraumatic Diagnostic Scale (PDS; Foa, 1996) and the Manchester short 
assessment of quality of life VN-12 (MANSA; Priebe et al., 1999) will be used to collect data 
on the severity of the PTSD symptoms and the quality of life.  
 
2.3.1 MINI 
The MINI is a short structured diagnostic interview which identifies the presence of axis 1 
diagnoses and possible comorbidity according to the DSM-IV (Lecrubier et al., 1997; 
Sheehan et al., 2006). In this study the Dutch version of the MINI will be used (Van Vliet, 
Leroy & Van Megen, 2000). 
Conducting the MINI will take about 20-30 minutes (Van Vliet & De Beurs, 2007). 
Participants will answer one or two screening questions per diagnostic section. When the 
participant answers positively to one of these screening questions, more questions follow to 
investigate corresponding diagnostic criteria (Lecrubier et al., 1997). 
The MINI is known for its good psychometric qualities. The inter-rater reliability (k = 
.88-1.00) and the test-retest reliability (k = .76-.93) are very good in 42 patients who 
participated in a reliability study (Lecrubier et al., 1997).  
 
2.3.2 CAPS 
The CAPS is a 30-item structured interview that identifies PTSD according to the DSM-IV. 
The CAPS is an international standard to diagnose PTSD and measures both frequency and 
intensity of PTSD symptoms (Blake et al., 1995). In this study the Dutch version of the CAPS 
will be used (Hovens et al., 1994). Conducting the CAPS will take about 45-60 minutes 
(Hovens, Luinge & Van Minnen, 2005). Answers are rated on a 5-point Likert scale, which 
consists of the following options: 0: “absent”, 1: “mild/subthreshold”, 2: 
“moderate/threshold”, 3: “severe/markedly elevated”, 4: “extreme/incapacitating” (Blake et 
al., 1990). A severity score of  65 suggests the diagnosis of severe PTSD (Blake et al., 
1990). 
The CAPS has very good psychometric qualities. The test-retest reliability (r = .77-
.96) and the internal consistency ( = .85-.87) are very good for the three symptom clusters 
re-experiencing, avoidance and arousal (Blake et al., 1995). In comparison to the Structured 
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Clinical Interview for DSM-IV (SCID-I), the CAPS showed good sensitivity ( = .84) and 
very good specifity ( = .95), with a kappa coefficient of .78 (Blake et al., 1995). 
 
2.3.3 PDS 
The PDS will be used to measure the severity of PTSD symptoms in participants before, 
during and after treatment. The PDS is a 17-item self-report, it assesses all DSM-IV criteria 
for PTSD and measures symptom severity (Foa, 1996; Foa, Cashman, Jaycox & Perry, 1997). 
In this study the Dutch version of the PDS will be used (Arntz, 1993). The PDS consists of 
four components: a trauma checklist, description of the most upsetting traumatic event, 
assessment of the 17 PTSD symptoms and assessment of interfering symptoms (Foa, 1996). 
Question 1-5 measure re-experiencing symptoms, question 6-11 measure avoidance and 
question 12-17 measure hyperarousal. The 17 PTSD symptoms are answered on a 4-point 
Likert scale, which consists of the following options: 0: “not at all or only one time”, 1: “once 
a week or less/once in a while”, 2: “2 to 4 times a week/half the time”, 3: “5 or more times a 
week/almost always” (Foa, 1996). The answers on the 17 PTSD symptoms sum up to scores 
from 0 to 51.  
 The PDS showed good psychometric qualities. The internal consistency for total 
symptom severity was good ( = .92). The three symptom clusters re-experiencing ( = .78), 
avoidance ( = .84) and arousal ( = .84) showed good internal consistency. The pre-test 
standard deviation for total symptom severity was Sdiff = 9.96, for re-experiencing it was 
Sdiff = 3.68, for avoidance Sdiff = 4.76 and for arousal Sdiff = 3.53 (Foa et al., 1997). The 
correlations between the three symptom clusters were large (r = .73-.94, p <.001) and the test-
retest reliability of PTSD diagnoses were satisfactory (k = .74) (Foa et al., 1997).  
 
2.3.4 MANSA 
The MANSA will be used to measure the quality of life of the participants before, during and 
after treatment. The version of the MANSA which will be used in this study consists of a 12 
item self-report questionnaire that measures the quality of life of the participant. A higher 
score represents a higher quality of life. In this study the Dutch version of the MANSA will 
be used, known as the ‘Manchester verkorte Kwaliteit van Leven meting’ (Van 
Nieuwenhuizen, Janssen–De Ruiter & Nugter, 2015). 
 The MANSA showed in comparison with the Lancashire Quality of Life Profile 
(LQLP) large Pearson’s correlations on the satisfaction ratings (r = .83-.99). The Cronbach’s 
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alpha for MANSA on the satisfaction ratings was .74 (Priebe et al., 1999) and the pre-test 
standard deviation was Sdiff = 5.27 (Van Nieuwenhuizen et al., 2015).  
 
2.4 Procedure 
Patients who are on the waiting list and seem eligible to participate in the study are 
approached by one of the therapists. The therapist explains the expected effectiveness of NET 
on PTSD symptoms. When a patient is interested in participating, a leaflet with more detailed 
information about NET is sent to their home address. For the patients who agree with the 
terms of the study, the baseline measurement will be planned. Within this measurement the 
MINI and the CAPS will be carried out by a trained psychologist of PsyQ, this psychologist is 
not connected to the study in any other way. The MINI and the CAPS will provide 
information about a PTSD diagnosis, participants with a severity score of  65 on the CAPS 
are included in the study. The aim is to conduct the MINI and CAPS two weeks before the 
actual start of the treatment.  
After completing the MINI and CAPS the participants will provide their demographic 
data (gender, age, cultural background) and fill in the PDS and MANSA. Patients who 
participate in the study all must sign the informed consent. The data of the MINI, CAPS, PDS 
and MANSA will form the baseline measure. To complete the baseline phase, participants 
will fill in the PDS and MANSA at home four times divided over 4 weeks. During the 
treatment phase participants complete the PDS and the MANSA at home four days after every 
NET session via Qualtrics. At the end of treatment all participants will do another CAPS and 
will fill in an exit questionnaire. Three months after the end of treatment a follow-up 
measurement will take place, this follow-up consists of the MINI, the CAPS, the PDS and the 
MANSA. 
The NET will be carried out by two experienced psychotherapists who are trained in 
NET. All participants will receive a maximum of 20 individual NET sessions, these sessions 
will last for approximately 90 minutes each.  
This research was approved by the research committee of PsyQ Den Haag Noord.  
 
2.5 Statistical analysis     
The data will be analysed using the statistical computer programme ‘Statistical Package for 
the Social Sciences’ version 24.0 (IBM SPSS Statistics).  
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To examine the first hypothesis the data of question 1, 2, 3, 4 and 5 of the PDS will be 
used: these questions refer to re-experiencing symptoms (Foa, 1996). The second hypothesis 
will be examined with question 1, 2, 3, 4 and 5 of the PDS and the number of completed 
NET-sessions. To examine the third hypothesis the data of the MANSA will be used.  
First there will be a visual inspection of the data, this is the dominant method of data 
evaluation in single-case research (Kazdin, 2017). The scores of the baseline phase will be 
calculated using the mean of the four baseline measurements and the scores of the treatment 
phase will be calculated using the mean of the last four treatment measurements. A time series 
analysis will provide a first sight at the PDS and MANSA, and will evaluate the correlation 
between the PDS and the number of completed NET-sessions (Matyas & Greenwood, 1990). 
This will be followed by a mixed models analysis for hypothesis 1 and 3, to see whether the 
PDS and MANSA scores are significantly changed at the end of the treatment phase 
compared to the baseline phase (Maric et al., 2015). The baseline and treatment measurements 
will be used as predictors in two SPSS mixed models analyses. The parameter b0 is the 
baseline intercept, b1 (phase) is the difference between the treatment and baseline in 
intercepts, b2 (time in phase) is the baseline slope and b3 (phase*time in phase) is the 
difference in rates between the treatment and baseline slopes (Maric et al., 2015). For the first 
hypothesis the analysis will use PDS question 1-5 as a dependent variable to measure re-
experiencing symptoms, for the third hypothesis the analysis will use the total MANSA score 
as a dependent variable to measure the quality of life.  
To see whether the change in PDS symptoms (hypothesis 1) and the change in quality 
of life (hypothesis 3) after completion of NET is clinically significant, a Reliable Change 
Index (RCI) with respect to changes in PTSD symptom scores will be used (Jacobson & 
Truax, 1991). The formula for the RCI = X2 – X1 / Sdiff. The X1 represents the mean score 
of the four baseline measurements and the X2 represents the mean score of the last four 
treatment measurements. The formula for the Sdiff = √𝟐(𝑺𝑬)𝟐. The formula to calculate SE = 
S1√𝟏 −  𝒓𝒙𝒙 where the S1 stands for the pre-test standard deviation in a relevant population 
(9.96 for the PDS and 5.27 for the MANSA; Foa et al., 1997; Priebe et al., 1999) and the rxx 
stands for the test-retest reliability of the questionnaire (.74 for both the PDS and MANSA; 
Foa et al., 1997; Van Nieuwenhuizen et al., 2015). The RCI defines whether the change in re-
experiencing symptoms and the change in quality of life is clinically significant (> 1.96 or     
< -1.96), based on how reliable the measure is.  
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3. Results 
3.1 Descriptive statistics 
The research included four participants who were patients of the department of Psychotrauma 
at PsyQ Den Haag. Table 2 shows the demographic data and the scores on the PDS and 
MANSA of the participants. The baseline phase represents the mean of the four baseline 
measurements and the treatment phase represents the mean of the last four treatment 
measurements. 
The assumption of the normal distribution of errors was checked by plotting the errors 
during the mixed models analyses. The assumption of linearity was checked as well: the 
scores looked linear by visual inspection of plots of the dependent and independent variable. 
Some measurements were missing, this was at random and therefore the estimation of the 
parameters was still sufficient (Maric et al., 2015). There were no missing items in the 
questionnaires. 
 
Table 2. Demographic data, total PDS scores, PDS scores for re-experiencing symptoms and 
MANSA scores of participants 
 Participant 1 Participant 2 Participant 3 Participant 4 
Demographic data 
Gender 
Age in years 
 
Female 
44 
 
Female 
35 
 
Female 
29 
 
Male 
56 
Total PDS score 
Baseline phase 
Treatment phase 
At 3 month follow-up 
 
57 
59 
49 
 
61 
46 
44 
 
44 
43 
* 
 
53 
53 
* 
Re-experiencing 
symptoms on PDS 
Baseline phase 
Treatment phase 
At 3 month follow-up 
 
 
16 
16 
14 
 
 
19 
17 
14 
 
 
14 
12 
* 
 
 
16 
15 
* 
MANSA-score 
Baseline phase 
Treatment phase 
At 3 month follow-up 
 
27 
29 
33 
 
40 
44 
46 
 
38 
43 
* 
 
47 
39 
* 
* Data not available 
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3.2 Participant 1 
Participant 1 was a 44-year old woman from Argentinian origin. At the time of treatment she 
lived with her current partner and their two children (11 and 4 years old). Her other three 
children (28, 27 and 25 years old) still lived in Argentina. She completed a study of child 
psychology (university level) in Argentina, at the time of treatment she was unemployed. She 
was diagnosed with PTSD due to physical abuse in her youth plus sexual and physical abuse 
in former relationships in her adulthood. Thereby, she experienced emotional abuse in her 
youth. Comorbid she suffered from recurring depressions. From the age of 8 until the age of 
17 she was dependent of Valium.  
The first participant completed all four baseline measurements, received 16 sessions of 
NET, completed the PDS and MANSA measurement after every session and completed the 
follow-up measurement. Figure 1 shows the different measurements of the baseline and 
treatment phase for the MANSA and for the re-experiencing symptoms on the PDS.  
When the baseline and treatment measurements are compared visually: the total PDS-
score seemed to increase, the score on re-experiencing symptoms in the PDS seemed to stay 
the same and the MANSA-score seemed to show an increase. According to the data of the 
follow-up, the participant seemed to improve on all three measurements: the total score on the 
PDS seemed to decrease, the score on the re-experiencing symptoms seemed to decrease and 
the score on the MANSA seemed to increase further. As shown in Table 3 and Table 4, none 
of the parameters were significant. The non-significant parameters meant that for re-
experiencing symptoms and the quality of life neither the baseline phase (p = .66 and p = .68) 
nor the treatment phase (p = .94 and p = .80) had a significant influence. There were no 
significant differences between the baseline and treatment measurements for re-experiencing 
symptoms (p = .71) and the quality of life (p = .67). Visual inspection did not show a positive 
correlation between the number of completed NET sessions and the reduction in re-
experiencing symptoms.  
The change in scores for re-experiencing on the PDS and the scores on the MANSA 
were not clinically significant (RCI re-experiencing symptoms = 0 and RCI MANSA = .53).  
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Figure 1. Re-experiencing symptoms on PDS and MANSA of participant 1. 
 
Table 3  
Estimates of Fixed Effects for participant 1 with PDS question 1-5 (re-experiencing 
symptoms) as a dependent variable 
   95% CI 95% CI 
 Estimate Std. 
Error 
Significance Lower Bound Upper 
Bound 
Intercept (b0) 17.19 3.22 .32 -1420.59 1454.96 
Phase (b1) -.51 4.67 .94 -531.59 530.57 
Timeinphase (b2) -.53 1.12 .66 -3.39 2.34 
Phase*Timeinphasej(b3) .51 1.24 .71 -3.08 4.09 
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Table 4  
Estimates of Fixed Effects for participant 1 with MANSA scores as a dependent variable 
   95% CI 95% CI 
 Estimate Std. 
Error 
Significance Lower 
Bound 
Upper 
Bound 
Intercept (b0) 29.58 5.39 <.001 16.02 43.15 
Phase (b1) -1.95 7.19 .80 -22.52 18.63 
Timeinphase (b2) -.75 1.76 .68 -4.66 3.15 
Phase*Timeinphasej(b3) .78 1.86 .67 -3.51 5.07 
      
3.3 Participant 2 
Participant 2 was a 35-year old single woman from Dutch origin. At the time of treatment she 
worked as a social worker in a rehabilitation centre. She was diagnosed with PTSD due to 
sexual abuse in her early childhood involving her father and physical abuse in a relationship 
which lasted for 5 years. Thereby, she experienced emotional abuse by her mother during her 
entire life. The year before treatment she had a manic-psychotic episode and was hospitalized. 
She suffered from a comorbid panic disorder. 
The second participant completed all four baseline measurements, received 16 
sessions of NET, completed the PDS and MANSA measurement after every session and 
completed the follow-up measurement. Figure 2 shows the different measurements of the 
baseline and treatment phase for the MANSA and for the re-experiencing symptoms on the 
PDS. 
When the baseline and treatment measurements are compared visually: the total PDS-
score and the score on re-experiencing symptoms seemed to decrease, the score on the 
MANSA seemed to increase. According to the data of the follow-up: the participant seemed 
to decrease further on the PDS-score and the score for re-experiencing symptoms, the 
MANSA score seemed to increase. As shown in Table 5 and Table 6, none of the parameters 
were significant. The non-significant parameters meant that for re-experiencing symptoms 
and the quality of life neither the baseline phase (p = .28 and p = .89) nor the treatment phase 
(p = .36 and p = .17) had a significant influence. There were no significant differences 
between the baseline and treatment phase for re-experiencing symptoms (p = .32) and the 
quality of life (p = .68). Visual inspection did not show a positive correlation between the 
number of completed NET sessions and the reduction in re-experiencing symptoms. 
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The change in scores for re-experiencing on the PDS and the scores on the MANSA 
were not clinically significant (RCI re-experiencing symptoms = -.28 and RCI MANSA = 
1.05).  
 
 
Figure 2. Re-experiencing symptoms on PDS and MANSA of participant 2. 
 
Table 5  
Estimates of Fixed Effects for participant 2 with PDS question 1-5 (re-experiencing 
symptoms) as a dependent variable 
   95% CI 95% CI 
 Estimate Std. 
Error 
Significance Lower 
Bound 
Upper 
Bound 
Intercept (b0) 17.35 1.04 <.001 15.03 19.67 
Phase (b1) -1.10 1.14 .36 -3.64 1.46 
Timeinphase (b2) .69 .61 .28 -.64 2.02 
Phase*Timeinphasej(b3) -.63 .60 .32 -1.96 .70 
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Table 6  
Estimates of Fixed Effects for participant 2 with MANSA scores as a dependent variable 
   95% CI 95% CI 
 Estimate Std. 
Error 
Significance Lower 
Bound 
Upper 
Bound 
Intercept (b0) 41.63 2.76 <.001 35.82 47.45 
Phase (b1) 4.93 3.45 .17 -2.35 12.21 
Timeinphase (b2) -.20 1.38 .89 -3.11 2.71 
Phase*Timeinphasej(b3) -.60 1.42 .68 -3.60 2.39 
 
3.4 Participant 3 
Participant 3 was a 29-year old single woman from Moroccan origin, who was born and 
raised in The Netherlands. At the time of treatment she was unemployed and lived with her 7-
year old son, who had impaired hearing and PDD-NOS. She was diagnosed with PTSD due to 
physical abuse by her father until the age of 20. Thereby, she experienced emotional abuse by 
her father until the age of 20 and by her former husband during their marriage which lasted 
for 10 months. She suffered from a comorbid depression. 
The third participant completed all four baseline measurements within one week. The 
participant received 9 sessions of NET, after 7 of the 9 sessions the participant completed the 
PDS and MANSA measurement: the data of session 4 and 8 were missing due to unknown 
reasons. There was no follow-up measurement. Figure 3 shows the different measurements of 
the baseline and treatment phase for the MANSA and for the re-experiencing symptoms on 
the PDS. 
When the baseline and treatment measurements are compared visually: the total PDS-
score and the score on re-experiencing symptoms seemed to decrease, the score on the 
MANSA seemed to increase. As shown in Table 7 and Table 8, none of the parameters were 
significant. The non-significant parameters meant that for re-experiencing symptoms and the 
quality of life neither the baseline phase (p = .71 and p = .52) nor the treatment phase (p = .16 
and p = .57) had a significant influence. There were no significant differences between the 
baseline and treatment phase for re-experiencing symptoms (p = .21) and the quality of life   
(p = .38). Visual inspection did not show a positive correlation between the number of 
completed NET sessions and the reduction in re-experiencing symptoms. 
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The change in scores for re-experiencing on the PDS and the scores on the MANSA 
were not clinically significant (RCI re-experiencing symptoms = -.28 and RCI MANSA = 
1.32).  
 
 
Figure 3. Re-experiencing symptoms on PDS and MANSA of participant 3. 
 
Table 7  
Estimates of Fixed Effects for participant 3 with PDS question 1-5 (re-experiencing 
symptoms) as a dependent variable 
   95% CI 95% CI 
 Estimate Std. 
Error 
Significance Lower 
Bound 
Upper 
Bound 
Intercept (b0) 14.09 .86 .01 8.93 19.24 
Phase (b1) -3.62 1.08 .16 -13.74 6.50 
Timeinphase (b2) -.20 .47 .71 -2.18 1.77 
Phase*Timeinphasej(b3) 1.02 .50 .21 -1.79 3.84 
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Table 8  
Estimates of Fixed Effects for participant 3 with MANSA scores as a dependent variable 
   95% CI 95% CI 
 Estimate Std. 
Error 
Significance Lower 
Bound 
Upper 
Bound 
Intercept (b0) 34.03 5.31 .53 -505204.82 505272.87 
Phase (b1) 13.54 7.41 .57 -36973.27 37000.35 
Timeinphase (b2) 1.91 2.13 .52 -19.32 23.13 
Phase*Timeinphasej(b3) -4.77 2.73 .38 -78.68 69.14 
 
3.5 Participant 4 
Participant 4 was a 56-year old man from Dutch origin. At the time of treatment he was 
unemployed and lived with his partner. He was diagnosed with PTSD due to sexual abuse by 
an older boy at his house. Thereby, he experienced emotional neglect by his parents, 
specifically his mother. Comorbid he suffered from a panic disorder, generalised anxiety 
disorder, dependence of benzodiazepines and recurring depressions. During NET he was 
hospitalized multiple times because of dissociative symptoms and thoughts about suicide, the 
hospitalization diverged from 1 night to three weeks. Participant 4 and the therapist made 
agreements on how to reduce dissociative symptoms during the sessions, these agreements 
existed of visual sensory exercises and throwing over a small object.  
The fourth participant completed three baseline measurements (missed the fourth 
measurement). The participant received 8 NET sessions, after 7 of the 8 sessions the 
participant completed the PDS and MANSA measurement: the data of session 4 was missing 
due to unknown reasons. There was no follow-up measurement. Figure 4 shows the different 
measurements of the baseline and treatment phase for the MANSA and for the re-
experiencing symptoms on the PDS. 
 When the baseline and treatment measurements are compared visually: the total PDS-
score seemed to stay the same, the scores on re-experiencing symptoms and the MANSA 
seemed to decrease. As shown in Table 9 and Table 10, one of the parameters had a 
significant influence: the treatment phase (p = .03) showed a significant decrease in quality of 
life, the baseline phase (p = .29) did not have a significant influence. For re-experiencing 
symptoms, neither the baseline phase (p = .64) nor the treatment phase (p = .88) had a 
significant influence. There were no significant differences between the baseline and 
treatment phase for re-experiencing symptoms (p = .64) and the quality of life (p = 1.00). 
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Visual inspection did not show a positive correlation between the number of completed NET 
sessions and the reduction in re-experiencing symptoms. 
The change in the score for re-experiencing on the PDS was not clinically significant 
(RCI re-experiencing symptoms = -.14). The change in the score on the MANSA was 
clinically significant (RCI MANSA = - 2.11).  
 
 
Figure 4. Re-experiencing symptoms on PDS and MANSA of participant 4. 
 
Table 9  
Estimates of Fixed Effects for participant 4 with PDS question 1-5 (re-experiencing 
symptoms) as a dependent variable 
   95% CI 95% CI 
 Estimate Std. 
Error 
Significance Lower 
Bound 
Upper 
Bound 
Intercept (b0) 15.03 21.94 1.00 -4702984.70 4703014.72 
Phase (b1) -1.00 5.71 .88 -38.67 36.67 
Timeinphase (b2) 1.00 1.35 .64 -68.85 70.85 
Phase*Timeinphasej(b3) -1.25 1.52 .64 -172.12 169.62 
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Table 10  
Estimates of Fixed Effects for participant 4 with MANSA scores as a dependent variable 
   95% CI 95% CI 
 Estimate Std. 
Error 
Significance Lower 
Bound 
Upper 
Bound 
Intercept (b0) 45.83 1.70 <.001 41.26 50.39 
Phase (b1) -9.19 2.08 .03 -16.14 -2.24 
Timeinphase (b2) 1.51 1.30 .29 -1.59 4.60 
Phase*Timeinphasej(b3) .00 1.33 1.00 -3.26 3.26 
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4. Discussion 
4.1 Summary of the results 
The aim of this study was to investigate the effectiveness of narrative exposure therapy (NET) 
on re-experiencing symptoms due to early childhood trauma-related posttraumatic stress 
disorder (PTSD).  
 The first hypothesis was not confirmed: there was no clinically significant decrease in 
the frequency of re-experiencing symptoms in this study. Visual inspection did not show a 
positive correlation between the number of completed NET sessions and the reduction in re-
experiencing symptoms in all four participants, which makes that the second hypothesis was 
not confirmed. The third hypothesis was not confirmed: there was no clinically significant 
increase in the quality of life in this study. 
 
A possible explanation for the non-significant findings is that NET holds on to evidence based 
techniques such as exposure, but in a different form or dose (Seidler & Wagner, 2006; 
Jongedijk, 2014). For instance, NET contains a relatively low dose of trauma exposure, 
because there is also space for positive memories (the flowers on the lifeline). In exposure 
treatments, the patient will only be confronted with the traumatic event. The patient will be 
asked to describe the traumatic event and relive it in their imagination (Seidler & Wagner, 
2006). This confrontation with the traumatic memory in a safe environment leads to 
extinction of the conditioned fear to the trauma memories and associated cues. Research by 
Tarrier et al. (1999) found that less frequent sessions or sessions with an extended between 
sessions interval of imaginal exposure caused that some patients became sensitised instead of 
desensitised. This suggests that the dose of exposure to the traumatic event is important to 
treat PTSD symptoms and might explain the null-effect in this current study. 
Another factor is that NET does not contain the repetitive factor which is formed by 
homework. In exposure treatments, this homework consists of listening to the audio-tape of 
their session at home multiple times a week (Seidler & Wagner, 2006). Research by Richards 
et al. (1994) found that homework in exposure treatments provided an extra reduction in 
PTSD symptoms and generalised this effect outside the therapy room. NET does not include 
homework, possibly allowing patients more room to avoid trauma-related stimuli during the 
week and reducing the beneficial effect of the exposure in other exposure treatments. 
 The results of this current study are in contradiction with the studies of Neuner et al. 
(2004) and Hijazi et al. (2014). Both studies showed that a couple of NET sessions already 
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contributed to a decrease in PTSD symptoms. These studies were conducted with Sudanese 
refugees in Uganda (Neuner et al., 2004) and with Iraqi refugees in the United States (Hijazi 
et al., 2014). This differed from the participants in this current study, who were treated for 
early childhood trauma, so none of these traumas were war-related. This suggests that NET is 
a better match to treat PTSD symptoms in war-related traumas than for early childhood 
trauma-related PTSD, which could explain the different outcomes. Future research could 
complement this study by researching the different treatment outcomes of NET in refugees 
with PTSD (Neuner et al., 2004; Hijazi et al., 2014) and in early childhood trauma-related 
PTSD as demonstrated in this current study.    
All four participants in this study had comorbid psychiatric diagnoses. This diverged 
from recurring depressions to dependence of benzodiazepines. The pilot study of Steuwe et al. 
(2016) evaluated NET as an add-on in patients with PTSD and comorbid borderline 
personality disorder. The researchers found a decrease in PTSD symptoms in this specific 
group of participants and suggested that NET possibly could be used with other comorbid 
psychiatric diagnoses as well. The comorbid psychiatric diagnoses in this current study 
differed from the comorbid borderline personality disorder in the study of Steuwe et al. 
(2016), this could possibly explain the null-effect in this current study. Future research could 
study the effect of NET on patients with early childhood trauma-related PTSD and comorbid 
borderline personality disorder, to compare the effect with the study of Steuwe et al. (2016). 
 
4.2 Strengths and limitations of the study 
A strength of this study is the use of state of the art measuring instruments, which are used in 
other peer reviewed studies on PTSD as well. The CAPS (Hovens et al., 1994; Blake et al., 
1995) and the PDS (Arntz, 1993; Foa, 1996) were used, both instruments are specifically 
designed to diagnose PTSD.  
 A strength of the single case experimental design is the possibility for the participant 
to evaluate and/or add minor changes to the intervention with the therapist without requiring 
changes for other participants (Kazdin, 2017). For example, participant 4 and the therapist 
made agreements on how to reduce dissociative symptoms during the sessions. These changes 
were not necessary for the other participants, but did not endanger the quality of the study 
because of the single case experimental design. Another strength of this specific design is the 
possibility for researchers to evaluate the changes and/or impact of NET for a single case, 
without the requirement of many participants (Kazdin, 2017).  
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The coordinating research focused on the effectiveness of NET on the diagnosis 
PTSD, and not specifically on re-experiencing symptoms. A strength of this study are the 
CAPS measurements at the beginning and end of treatment. In this semi-structured interview 
the interviewer asks questions about the specific symptoms of the PTSD diagnosis, so there is 
also attention for the re-experiencing symptoms. Research showed that the PDS performed 
well in relation to the CAPS, but has a tendency to produce an overestimation of the PTSD 
diagnosis (Griffin, Uhlmansiek, Resick & Mechanic, 2004). A possible explanation is that the 
CAPS measures both the frequency and intensity of the PTSD-symptoms, the PDS only 
measures the severity of the PTSD symptoms. This overestimation was demonstrated in the 
current study as well, but did not provide any problems: it was already present at the pre-test 
and therefore provides no explanation for the null-effect found in this study. 
Re-experiencing symptoms have not been studied apart from other PTSD-symptoms 
in therapy effect studies before. Re-experiencing symptoms were researched from multiple 
points of view: the decrease, the correlation with the completed number of NET-sessions and 
the clinical significance of this decrease were researched. The quality of life was researched 
from multiple points of view as well: the increase and the clinical significance of this increase 
were researched. By studying the concepts of both re-experiencing symptoms and the quality 
of life from multiple points of view, the internal validity to determine the effectiveness of 
NET was increased. Therefore, the null-effect demonstrated in this current study should be 
taken seriously.  
 
A concern of the single case experimental design is the external validity, specifically the 
generalizability of the results, since results found in this study may not be generalizable to 
subjects outside the sample (Kazdin, 2017).  
By using multiple points of view the chance of finding a false positive increased as 
well. The more analyses are performed, the bigger the chance for finding a false positive 
(Kazdin, 2017), this is a concern for this type of (statistical) analyses. 
The follow-up data of two participants missed, with this data a more complete view of 
the effectiveness of NET could be demonstrated. These two participants did not want to 
participate in the study anymore for unknown reasons, this is a limitation of the current study. 
Previous studies showed a delayed effect of NET six months after the end of treatment 
(Jongedijk, 2014). For none of the participants the data reached further than three months 
after the ending of NET. There is a possibility that the re-experiencing symptoms and the 
quality of life improved (further) more than six months after the end of treatment. 
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4.3 Clinical implications 
This study does not demonstrate clinical effectiveness of NET on re-experiencing symptoms 
or on quality of life in patients with early childhood trauma-related PTSD. Over the years, 
NET is applied more often (Jongedijk, 2014), but our results warrant further dissemination in 
patients with early childhood trauma-related PTSD since our results are in contradiction with 
other studies (Neuner et al., 2004; Dõmen et al., 2012, as cited in Jongedijk, 2014; Hijazi et 
al., 2014; Steuwe et al., 2016).  
 
4.4 Future research 
Future research could complement this study by deepening and widening the results. The 
current study included 4 participants as single cases, this is a limitation. Adding more single 
cases is recommended to determine the effectiveness of NET in early childhood trauma-
related PTSD. 
Future research could also study the possible underlying cohesion between the 
decrease in re-experiencing symptoms and the increase in quality of life. This possible 
underlying cohesion was not researched in this study, because there were only 4 single cases 
included. Further research could complement this current study on re-experiencing symptoms 
and the quality of life in early childhood trauma-related PTSD. A possible hypothesis could 
be that when re-experiencing symptoms decrease, this unfolds in an increase in the quality of 
life.  
Another suggestion is to use a different participant group to compare the results of this 
study. Future research could focus on the differences between early childhood trauma-related 
PTSD with and without comorbid psychiatric diagnoses. Or on the differences between early 
childhood trauma-related PTSD in the primary mental healthcare and the secondary mental 
healthcare. Results from more patients with early childhood trauma-related PTSD are 
necessary to determine the effectiveness of NET.  
 
4.5 Conclusion 
In this study the effectiveness of NET on re-experiencing symptoms due to early childhood 
trauma-related PTSD was researched. It can be concluded that NET does not have a clinically 
significant effect on the frequency of re-experiencing symptoms and the quality of life in 
patients with PTSD due to early childhood trauma in this study. Further research on NET in 
early childhood trauma-related PTSD and re-experiencing symptoms is required.  
 29 
References 
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental 
disorders (5th ed.). Washington: DC.  
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental 
disorders (4th ed., text rev.). Washington: DC. 
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental 
disorders (4th ed.). Washington: DC.  
American Psychiatric Association. (1980). Diagnostic and statistical manual of mental 
disorders (3rd ed.). Washington: DC.  
Arntz, A. (1993). Dutch translation of the PSS-SR. Maastricht, The Netherlands. 
Astin, M. C., Ogland-Hand, S. M., Coleman, E. M., & Foy, D. W. (1995). Posttraumatic 
stress disorder and childhood abuse in battered women: Comparisons with maritally 
distressed women. Journal of Consulting and Clinical psychology, 63, 308-312. 
Barlow, D. H., Hersen, M., & Jackson. (1973). Single-case experimental designs. Archives of 
General Psychiatry, 29, 319-325. 
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., 
& Keane, T. M. (1995). The development of a clinician-administered PTSD scale. 
Journal of Traumatic Stress, 8, 75-90. 
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Klauminzer, G., Charney, D. 
S., & Keane, T. M. (1990). Clinician-administered PTSD scale (CAPS). Boston: MA: 
National Centre for Posttraumatic Stress Disorder, Behavioural Science Division-
Boston. 
Brewin, C. R. (2015). Re-experiencing traumatic events in PTSD: New avenues in research 
on intrusive memories and flashbacks. European Journal of Psychotraumatology, 6, 1-
5.  
Brewin, C. R. (2014). Episodic memory, perceptual memory, and their interaction: 
Foundations for a theory of posttraumatic stress disorder. Psychological Bulletin, 140, 
69-97.  
Brewin, C. R., & Holmes, E. A. (2003). Psychological theories of posttraumatic stress 
disorder. Clinical Psychology, 23, 339-376. 
Cloitre, M., Stovall-McClough, K. C., Nooner, K., Zorbas, P., Cherry, S., Jackson, C. L., … 
Petkova, E. (2010). Treatment for PTSD related to childhood abuse: A randomized 
controlled trial. American Journal of Psychiatry, 167, 915-924. 
 30 
Cusack, K., Jones, D. E., Forneris, C. A., Wines, C., Sonis, J., Cook-Middleton, J., … 
Gaynes, B. N. (2016). Psychological treatments for adults with posttraumatic stress 
disorder: A systematic review and meta-analysis. Clinical Psychology Review, 43, 
128-141. 
De Vries, G. J., & Olff, M. (2009). The lifetime prevalence of traumatic events and 
posttraumatic stress disorder in The Netherlands. Journal of Traumatic Stress, 22, 
259-267.  
Dõmen, I., Ejiri, M., & Mori, S. (2012). Narrative exposure therapy for the treatment of 
complex PTSD. The Japanese Journal of Psychotherapy, 13, 67-74. 
Ehlers, A., Hackmann, A., & Michael, T. (2004). Intrusive re-experiencing in post-traumatic 
stress disorder: Phenomenology, theory, and therapy. Memory, 12, 403-415.  
Ehlers, A., & Clark, D. M. (2000). A cognitive model of posttraumatic stress disorder. 
Behaviour Research and Therapy, 38, 319-345. 
Ehring, T., Welboren, R., Morina, N., Wicherts, J. M., Feitag, J., & Emmelkamp, P. (2014). 
Meta-analysis of psychological treatments for posttraumatic stress disorder in adult 
survivors of childhood abuse. Clinical Psychology Review, 34, 645-657. 
Foa, E., Cashman, L., Jaycox, L., & Perry, K. (1997). The validation of a self-report measure 
of PTSD: The posttraumatic diagnostic scale. Psychological Assessment, 9, 445-451. 
Foa, E. (1996). Posttraumatic diagnostic scale manual. Minneapolis, MN: National Computer 
Systems. 
Griffin, M. G., Uhlmansiek, M. H., Resick, P. A., & Mechanic, M. B. (2004). Comparison of 
the posttraumatic stress disorder scale versus the clinician-administered posttraumatic 
stress disorder scale in domestic violence survivors. Journal of Traumatic Stress, 16, 
497-503. 
Hijazi, A. M., Lumley, M. A., Ziadni, M. S., Haddad, L., Rapport, L. J., & Arnetz, B. B. 
(2014). Brief narrative exposure therapy for posttraumatic stress in Iraqi refugees: A 
preliminary randomized clinical trial. Journal of Traumatic Stress, 27, 314-322. 
Hovens, J. E., Luinge, B., & Van Minnen, A. (2005). Het Klinisch Interview voor PTSS (KIP) 
[The clinical interview for PTSD (CAPS)]. Nijmegen: Cure & Care Publishers.  
Hovens, J.E., Van der Ploeg, H.M., Klaarenbeek, M.T.A., Bramsen, I., Schreuder, J. N., & 
Vladar-Rivero, V. (1994). The assessment of posttraumatic stress disorder with the 
clinician administered PTSD scale: Dutch results. Journal of Clinical Psychology, 50, 
325-340.  
 31 
Jacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining 
meaningful change in psychotherapy research. Journal of Consulting and Clinical 
Psychology, 59, 12-19.  
Jongedijk, R. (2014). Levensverhalen en psychotrauma. Narratieve exposure therapie in 
theorie en praktijk. Amsterdam: Uitgeverij Boom. 
Kazdin, A. E. (2017). Research design in clinical psychology. Boston: MA: Pearson. 
Kessler, R. C., Sonnega, A., Bromet, E., Hughes, M., & Nelson, C. B. (1995). Posttraumatic 
stress disorder in the national comorbidity survey. Archives of General Psychiatry, 52, 
1048-1060. 
Lecrubier, Y., Sheehan, D. V., Weiller, E., Amorim, P., Bonora, I., Harnett-Sheehan, K., 
Janavs, J., & Dunbar, G. C. (1997). The mini international neuropsychiatric interview 
(MINI). A short diagnostic structured interview: Reliability and validity according to 
CIDI. European psychiatry, 12, 224-231. 
Maric, M., De Haan, E., Hogendoorn, S. M., Wolters, L. H., & Huizenga, H. M. (2015). 
Evaluating statistical and clinical significance of intervention effects in single-case 
experimental designs: An SPSS method to analyze univariate data. Behavior Therapy, 
46, 23-241. 
Matyas, T. A., & Greenwood, K. M. (1990). Visual analysis of single-case time series: Effects 
of variability, serial dependence, and magnitude of intervention effects. Journal of 
Applied Behavior Analysis, 23, 341-351. 
Neuner, F., Schauer, M., Klaschik, C., Karunakara, U., & Elbert, T. (2004). A comparison of 
narrative exposure therapy, supportive counseling and psychoeducation for treating 
posttraumatic stress disorder in an African refugee settlement. Journal of Consulting 
and Clinical Psychology, 72, 579-587. 
Priebe, S., Huxley, P., Knight, S., & Evans, S. (1999). Application and results of the 
Manchester short assessment of quality of life (MANSA). International Journal of 
Social Psychiatry, 45, 7-12. 
Rachman, S. (2013). Anxiety. East Sussex: Psychology Press Ltd. 
Richards, D.A., Lovell, K., & Marks, I. M. (1994). Post-traumatic stress disorder: Evaluation 
of a behavioral treatment program. Journal of Traumatic Stress, 7, 669-680. 
Robjant, K., & Fazel, M. (2010). The emerging evidence for narrative exposure therapy: A 
review. Clinical Psychology Review, 30, 1030-1039. 
 32 
Seidler, G. H., & Wagner, F. E. (2006). Comparing the efficacy of EMDR and trauma-
focused cognitive-behavioural therapy in the treatment of PTSD: A meta-analytic 
study. Psychological Medicine, 36, 1515-1522. 
Sheehan, D., Janavs, J., Baker, R., Harnett-Sheehan, K., Knapp, E., & Sheehan, M. (2006). 
Mini international neuropsychiatric interview. Tampa: University of South Florida. 
Steuwe, C., Rullkötter, N., Ertl, V., Berg, M., Neuner, F., Beblo, T., & Driessen, M. (2016). 
Effectiveness and feasibility of narrative exposure therapy (NET) in patients with 
borderline personality disorder and posttraumatic stress disorder: A pilot study. BMC 
Psychiatry, 16, 1-11. 
Stovall-McClough, K. C., & Cloitre, M. (2006). Unresolved attachment, PTSD, and 
dissociation in women with childhood abuse histories. Journal of Consulting and 
Clinical Psychology, 74(2), 219. 
Tarrier, N., Pilgrim, H., Sommerfield, C., Faragher, B., Reynolds, M., Graham, E., & 
Barrowclough, C. (1999). A randomized trial of cognitive therapy and imaginal 
exposure in the treatment of chronic posttraumatic stress disorder. Journal of 
Consulting and Clinical Psychology, 67, 13-18. 
Van Nieuwenhuizen, C., Janssen-De Ruijter, L., & Nugter, A. (2015). Manchester verkorte 
Kwaliteit van Leven meting (MANSA) [Dutch translation of the Manchester Short 
Assessment of Quality of Life] –  Interview available from Tijdschrift voor Psychiatrie 
at http://www.tijdschriftvoorpsychiatrie.nl. 
Van Vliet, I. M., & De Beurs, E. (2007). Het mini internationaal neuropsychiatrisch interview 
(MINI) [Mini international neuropsychiatric interview]. Tijdschrift voor psychiatrie, 
49, 393-397. 
Van Vliet, I. M., Leroy, H., & Van Megen, H. J. G. M. (2000). MINI internationaal 
neuropsychiatrisch interview [Dutch translation of the MINI international 
neuropsychiatric interview] –  Interview available from Tijdschrift voor Psychiatrie at 
http://www.tijdschriftvoorpsychiatrie.nl. 
Yehuda, R., Halligan, S. L., & Grossman, R. (2001). Childhood trauma and risk for PTSD: 
Relationship to intergenerational effects of trauma, parental PTSD, and cortisol 
excretion. Development and Psychopathology, 13, 733-753. 
